Entera Stock Story

ENTX
 Stock
  

USD 1.45  0.06  3.97%   

As many of us are excited about healthcare space, we will review both, Entera Bio and Brickell Biotech as a potential short-term opportunity. We are going to inspect some of the competitive aspects of both Entera and Brickell.
Published over three months ago
View all stories for Entera Bio | View All Stories

Entera Bio Current Investor Sentiment

Investor biases related to Entera Bio's public news can be used to forecast risks associated with investment in Entera. The trend in average sentiment can be used to explain how an investor holding Entera can time the market purely based on public headlines and social activities around Entera Bio. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Entera Bio's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Entera Bio's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Entera Bio's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Entera Bio.
Will Entera Bio (NASDAQ:ENTX) investors shift to Brickell (NASDAQ:BBI)?
By analyzing existing basic indicators between Entera Bio and Brickell, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Brickell with a short position in Entera Bio. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Entera Bio has an asset utilization ratio of 6.62 percent. This suggests that the company is making $0.0662 for each dollar of assets. An increasing asset utilization means that Entera Bio is more efficient with each dollar of assets it utilizes for everyday operations.

Watch out for price decline

Please consider monitoring Entera Bio on a daily basis if you are holding a position in it. Entera Bio is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Entera Bio stock to be traded above the $1 level to remain listed. If Entera Bio stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Entera Bio's Liquidity

Entera Bio financial leverage refers to using borrowed capital as a funding source to finance Entera Bio ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Entera Bio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Entera Bio's total debt and its cash.

How does Entera utilize its cash?

To perform a cash flow analysis of Entera Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Entera Bio is receiving and how much cash it distributes out in a given period. The Entera Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Entera Bio Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Entera Bio reported Net Cash Flow from Operations of (9.06 Million) in 2021

Acquisition by Hillel Galitzer of 60000 shares of Entera Bio subject to Rule 16b-3

Legal trades by Entera Bio insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Entera insider trading alert for grant of stock option (right to buy) by Hillel Galitzer, Chief Operating Officer, on 4th of April 2022. This event was filed by Entera Bio Ltd with SEC on 2022-04-04. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Entera Bio

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Now, let's check Entera Bio revenue. Based on the latest financial disclosure, Entera Bio reported 627 K of revenue. This is 99.99% lower than that of the Healthcare sector and 99.92% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.99% higher than that of the firm. As for Brickell Biotech we see revenue of 327 K, which is 99.96% lower than that of the Biotechnology

Sector
742.9 M
ENTX627,0000.0843
Sector742.91 Million99.87
BBI327,0000.044

Will Entera price slide impact its balance sheet?

Current potential upside is at 4.37. Entera Bio exhibits very low volatility with skewness of 0.65 and kurtosis of 2.44. However, we advise investors to further study Entera Bio technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Entera Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Entera Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Entera Bio Implied Volatility

Entera Bio's implied volatility exposes the market's sentiment of Entera Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Entera Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Entera Bio stock will not fluctuate a lot when Entera Bio's options are near their expiration.

Our Takeaway on Entera Bio Investment

While some other firms in the biotechnology industry are either recovering or due for a correction, Entera Bio may not be performing as strong as the other in terms of long-term growth potentials. To sum up, as of the 8th of March 2022, our research shows that Entera Bio is a rather relatively risky investment opportunity with a close to average probability of financial unrest in the next two years. From a slightly different view, the entity currently appears to be undervalued. Our up-to-date 90 days advice on the company is Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Entera Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com